Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $511.05M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 1.04M
Average 0.87M
TLS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Telos CorporationNASDAQ: TLS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $5.58M, compared with -$6.13M a year earlier. Trailing-twelve-month EBITDA was -$13.5M.
Context
- EBITDA amounted to 15.3% of revenue in FY2025, down 21.6 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $36.12M (+243.3%) for the fiscal year ending Dec 2026, a step up from the +37.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.58M+141.4% QoQ
- Last fiscal yearDec 2025
- -$25.21M+37.0% YoY
- LTMMar 2026
- -$13.5M+67.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +191.1% | +175.1% | -16.0 pp |
| 1 year | +37.0% | +243.3% | +206.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (25.21M) USD
- Year-over-year change
- +37.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.21M) | +37.0% |
| FY2024 | 2024-12-31 | (39.98M) | -65.4% |
| FY2023 | 2023-12-31 | (24.17M) | +48.1% |
| FY2022 | 2022-12-31 | (46.61M) | -26.8% |
| FY2021 | 2021-12-31 | (36.76M) | — |
EBITDA vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +67.9% is the 4th highest of 10, against a peer median of +14.9%.
- EBITDA amounts to 7.4% of revenue for TLS, versus a peer median of 11.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $349.55M USD | -13.3% | +5.0% | 20.1% | |
| LTM Mar 2026 | $176M USD | +124.1% | +36.2% | 2.4% | |
| LTM Mar 2026 | $76.13M USD | +14.9% | +18.7% | 12.1% | |
| LTM Mar 2026 | $59.66M USD | -2.0% | — | 24.3% | |
| LTM Mar 2026 | $53.31M USD | -10.8% | -12.2% | 6.8% | |
| LTM Mar 2026 | $37.81M USD | +110.6% | — | 12.5% | |
| LTM Mar 2026 | $31.54M USD | -24.2% | -21.2% | 10.6% | |
| LTM Mar 2026 | $15.85M USD | +17.6% | +129.2% | 7.8% | |
| LTM Mar 2026 | -$13.5M USD | +67.9% | — | 7.4% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | -CN¥33.25M CNY | +92.9% | — | — |
| Peer median (excluding TLS) | — | +14.9% | +11.8% | 11.4% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 242.43M | 216.89M | 145.38M | 108.27M | 164.81M |
| Cost of Revenue | 156.4M | 137.84M | 92.44M | 73.84M | 103.79M |
| Gross Profit | 86.03M | 79.04M | 52.94M | 34.43M | 61.02M |
| Gross Margin | 35.5% | 36.4% | 36.4% | 31.8% | 37.0% |
| Research & Development | 19.1M | 16.92M | 12.25M | 8.44M | 7.06M |
| Selling, General & Admin | 108.4M | 115.98M | 81.01M | 75.49M | 78.93M |
| Operating Expenses | 127.49M | 132.89M | 93.26M | 90.3M | 85.53M |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| EBITDA | (36.76M) | (46.61M) | (24.17M) | (39.98M) | (25.21M) |
| EBITDA Margin | -15.2% | -21.5% | -16.6% | -36.9% | -15.3% |
| Operating Income | (41.46M) | (53.85M) | (40.32M) | (55.87M) | (24.47M) |
| Operating Margin | -17.1% | -24.8% | -27.7% | -51.6% | -14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 777K | 874K | 786K | 644K | 553K |
| Other Income / Expenses | (1.7M) | 476K | 5.93M | 3.38M | (12.74M) |
| Income Before Tax | (43.16M) | (53.37M) | (34.39M) | (52.49M) | (37.21M) |
| Pre-Tax Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.6% |
| Income Tax Expense | (28K) | 54K | 36K | 26K | (663K) |
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Net Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.2% |
| EPS (Basic) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| EPS (Diluted) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| Weighted Avg Shares | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
| Weighted Avg Shares (Diluted) | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$6.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.